Medical Affairs

Congress posters & Presentations

Congress materials from Beren-sponsored research

Poster
NPCCSS
Survival
Poster: Survival outcomes by baseline disease burden in participants with infantile-onset Niemann-Pick disease type C treated with adrabetadex

May 31, 2026

Ara Parseghian Medical Research Fund 2026
Poster
NPCCSS
Poster: Outcomes in participants with infantile-onset Niemann-Pick disease type C receiving prompt and sustained treatment with adrabetadex

May 31, 2026

Ara Parseghian Medical Research Fund 2026
Poster
Poster: Early evidence of an emerging NPC treatment paradigm: adrabetadex use alongside arimoclomol and/or N‑acetyl‑L‑leucine

May 31, 2026

Ara Parseghian Medical Research Fund 2026
Poster
Preclinical
Poster: Adrabetadex alone or in combination with arimoclomol and levacetylleucine promotes oligodendrocyte proliferation, synaptic network growth, and myelination in an in vitro mouse model of Niemann-Pick disease type C

May 31, 2026

Ara Parseghian Medical Research Fund 2026
Poster
Preclinical
Poster: Mechanism of action of adrabetadex for treatment of Niemann-Pick disease type C

May 31, 2026

Ara Parseghian Medical Research Fund 2026
Poster
Preclinical
Poster: Disease modifying effects of centrally administered adrabetadex for treatment of Niemann-Pick disease type C

May 31, 2026

Ara Parseghian Medical Research Fund 2026
Poster
Biomarkers
NPCCSS
Survival Analysis
Efficacy of Intrathecal Adrabetadex in Infantile-Onset Niemann-Pick Disease Type C is Supported by Survival, Clinical, and Biomarker Data

May 17, 2026

Society for Inherited Metabolic Disorders 2026
Presentation
Biomarkers
NPCCSS
Survival Analysis
Presentation: Survival, Clinical, and Biomarker Data Support the Efficacy of Intrathecal Adrabetadex in Niemann-Pick Disease Type C​

March 12, 2026

American College of Medical Genetics and Genomics 2026
ePoster
NPCCSS
Survival Analysis
Substantial Survival Benefit and Slowing of Disease Progression With Adrabetadex Treatment in Individuals With Infantile-onset Niemann-pick Disease Type C (NPC)

February 6, 2026

WORLDSymposium 2026
Poster
NPCCSS
Survival Analysis
Substantial Survival Benefit and Slowing of Disease Progression With Adrabetadex Treatment in Individuals With Infantile-onset Niemann-pick Disease Type C (NPC)

February 6, 2026

WORLDSymposium 2026

Contact Beren Medical

If you have additional questions related to information provided on this website or other medical inquiries, please contact the Beren Medical Affairs team at medinfo@berentx.com.

The information provided on this website is provided by the Beren Therapeutics P.B.C. (“Beren”) Medical Affairs team for healthcare professionals in the US. It is designed to provide self-service access to medical information and medical affairs content about Beren products, pipeline, and therapeutic areas of interest including clinical data, research developments, congress materials, and publications. Certain materials such as posters and presentations presented in this website are a result of Beren-sponsored research and are not intended to be a comprehensive overview of all information and materials presented at a particular congress. The website is intended to provide scientifically balanced information and educational resources and may include information related to products or indications that have not been approved by the US Food and Drug Administration. The information provided is not intended as medical advice and does not replace independent medical judgement. By searching this website, you confirm the unsolicited nature of your inquiry. Please confirm that you agree and that you are a registered healthcare professional registered to practice in the US.

Are you a US healthcare provider?

No